ArticleAntimicrobial agents and chemotherapy2012
Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-ResistantFrontiers in medicine · 2021Pooled it
- Overview of the ASM-IISc Symposium on the One Health Approach to AMR in Bengaluru, India.mSphere · 2026Article
- Genomic Epidemiology, Antimicrobial Resistance, and Virulence of ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Clade-specific evolution and genome plasticity underlying antimicrobial resistance in Enterococcus faecium.Archives of microbiology · 2026Review
- Saturated fatty acids enhance daptomycin activity in a Fak-dependent manner in enterococci.Microbiology (Reading, England) · 2026Article
- Daptomycin failure in the treatment of Enterococcus faecium bacteremia: microbiological insights and the importance of dual therapy including beta-lactam.Critical care (London, England) · 2026Article
- Genomic surveillance of vancomycin-resistant Enterococcus faecium: a study on Resistome, Plasmidome, and mobilome profiling.Current genetics · 2025Article
- Evolution under vancomycin selection drives divergent collateral sensitivity patterns inProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Development of VRE meningitis due to haematogenous spread while on high-dose daptomycin therapy.JAC-antimicrobial resistance · 2023Article
- The LiaFSR-LiaX System Mediates Resistance of Enterococcus faecium to Peptide Antibiotics and to Aureocin A53- and Enterocin L50-Like Bacteriocins.Microbiology spectrum · 2023Article
- Penicillin-Binding Proteins and Alternative Dual-Beta-Lactam Combinations for Serious Enterococcus faecalis Infections with Elevated Penicillin MICs.Antimicrobial agents and chemotherapy · 2023Article
- Vancomycin Resistance inMicroorganisms · 2022Review
- Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in anAntimicrobial agents and chemotherapy · 2022Article
- Antimicrobial Susceptibility Testing for Enterococci.Journal of clinical microbiology · 2022Review
- Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates.Microbiology spectrum · 2022Article
- Acquisition of Daptomycin Resistance byFrontiers in microbiology · 2022Article
- An orally administered drug prevents selection for antibiotic-resistant bacteria in the gut during daptomycin therapy.Evolution, medicine, and public health · 2022Article
- Daptomycin Resistance Occurs Predominantly inFrontiers in microbiology · 2021Article
- Resistance in Vancomycin-Resistant Enterococci.Infectious disease clinics of North America · 2020Review
- Two Cases of Vancomycin-ResistantOpen forum infectious diseases · 2020Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
Mutations in liaFSR, a three-component regulatory system controlling cell-envelope stress response, were recently linked with the emergence of daptomycin (DAP) resistance in enterococci. Our previous work showed that a liaF mutation increased the DAP MIC of a vancomycin-resistant Enterococcus faecalis strain from 1 to 3 μg/ml (the DAP breakpoint is 4 μg/ml), suggesting that mutations in the liaFSR system could be a pivotal initial event in the development of DAP resistance. With the hypothesis that clinical enterococcal isolates with DAP MICs between 3 and 4 μg/ml might harbor mutations in liaFSR, we studied 38 Enterococcus faecium bloodstream isolates, of which 8 had DAP MICs between 3 and 4 μg/ml by Etest in Mueller-Hinton agar. Interestingly, 6 of these 8 isolates had predicted amino acid changes in the LiaFSR system. Moreover, we previously showed that among 6 DAP-resistant E. faecium isolates (MICs of >4 μg/ml), 5 had mutations in liaFSR. In contrast, none of 16 E. faecium isolates with a DAP MIC of ≤2 μg/ml harbored mutations in this system (P < 0.0001). All but one isolate with liaFSR changes exhibited DAP MICs of ≥16 μg/ml by Etest using brain heart infusion agar (BHIA), a medium that better supports enterococcal growth. Our findings provide a strong association between DAP MICs within the upper susceptibility range and mutations in the liaFSR system. Concomitant susceptibility testing on BHIA may be useful for identifying these E. faecium first-step mutants. Our results also suggest that the current DAP breakpoint for E. faecium may need to be reevaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.